Seeking Alpha

Merck (MRK +0.5%) gives a ray hope to its dwindling pipeline, after saying that Phase 2b studies...

Merck (MRK +0.5%) gives a ray hope to its dwindling pipeline, after saying that Phase 2b studies of MK-3102, its investigational once-weekly treatment for Type 2 diabetes , significantly lowered blood sugar when compared with a placebo. The pharmaceutical giant presented the data at the annual meeting of the European Association for the Study of Diabetes in Berlin, noting the results were very encouraging and it plans to begin Phase 3 studies very soon.
Comments (1)
  • biochemist
    , contributor
    Comments (423) | Send Message
     
    The MRK pipeline is not "dwindling" at this point. The news on MK-3102 (once daily DPP-4 inhibitor) is just the latest in a string of good news for MRK, including the early end to the odanacatib outcomes study for "robust efficacy".

     

    http://seekingalpha.co...
    8 Oct 2012, 05:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs